Gnanasakthy A, Russo J, Gnanasakthy K, Harris N, Castro C. A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemp Clin Trials. 2022 Sep;120:106860. doi: 10.1016/j.cct.2022.106860
Anderson C, Smitherman AB, Meernik C, Edwards TP, Deal AM, Cannizzaro N, Baggett CD, Chao C, Nichols HB. Patient/provider discussions about clinical trial participation and reasons for nonparticipation among adolescent and young adult women with cancer. J Adolesc Young Adul. 2020 Feb;9(1):41-6. doi: 10.1089/jayao.2019.0078
Ling W, Nadipelli VR, Ronquest N, Albright VA, Aldridge AP, Learned SM, Mehra V, Heidbreder C. Remission from chronic opioid use-studying environmental and socio-economic factors on recovery (RECOVER): study design and participant characteristics. Contemp Clin Trials. 2019 Jan;76:93-103. doi: 10.1016/j.cct.2018.11.015
Blonde L, Brunton SA, Chava P, Zhou R, Meyers J, Davis KL, Dalal MR, Digenio A. Achievement of target A1C <7.0% (<53 mmol/mol) by U.S. type 2 diabetes patients treated with basal insulin in both randomized controlled trials and clinical practice. Diabetes Spectr. 2018 Nov;31(4). doi: 10.2337/ds17-0082
Setji T, Hopkins TJ, Jimenez M, Manning E, Shaughnessy M, Schroeder R, Mendoza-Lattes S, Spratt S, Westover J, Aronson S. Rationalization, development, and implementation of a preoperative diabetes optimization program designed to improve perioperative outcomes and reduce cost. Diabetes Spectr. 2017 Aug;30(3):217-23.
Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL. Inclusion of patient-reported outcome measures in registered clinical trials: evidence from ClinicalTrials.gov (2007-2013). Contemp Clin Trials. 2015 Apr 18;43:1-9. doi: 10.1016/j.cct.2015.04.004
Gnanasakthy A, DeMuro C, Boulton C. Integration of patient-reported outcomes in multiregional confirmatory clinical trials. Contemp Clin Trials. 2013 May 1;35(1):62-9.
Hareendran A, Gnanasakthy A, Winnette RM, Revicki D. Capturing patients' perspectives of treatment in clinical trials/drug development. Contemp Clin Trials. 2012 Jan;33(1):23-8.
Stull DE, Wiklund I, Gale R, Capkun-Niggli G, Houghton K, Jones P. Application of latent growth and growth mixture modeling to identify and characterize differential responders to treatment for COPD. Contemp Clin Trials. 2011 Nov 1;32(6):818-28.
Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, Martin SA. Toward development of a fibromyalgia responder index and disease activity score: oMERACT module update. J Rheumatol. 2011 Jul 1;38(7):1487-95.
Choy EH, Arnold LM, Clauw DJ, Crofford LJ, Glass JM, Simon LS, Martin SA, Strand CV, Williams DA, Mease PJ. Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. J Rheumatol. 2009 Oct 1;36(10):2330-4.
Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, Glass JM, Martin SA, Morea J, Simon L, Strand CV, Williams DA. Fibromyalgia syndrome module at OMERACT 9: domain construct. J Rheumatol. 2009 Oct 1;36(10):2318-29.
Mease PJ, Russell IJ, Arnold LM, Florian H, Young JP, Martin SA, Sharma U. A randomized, double-blind, placebo-controlled, phase III trial of pregabalin in the treatment of patients with fibromyalgia. J Rheumatol. 2008 Mar;35(3):502-14.
Mease P, Arnold LM, Bennett R, Boonen A, Buskila D, Carville S, Chappell A, Choy E, Clauw D, Dadabhoy D, Gendreau M, Goldenberg D, Littlejohn G, Martin SA. OMERACT 8 workshop: fibromyalgia syndrome. J Rheumatol. 2007 Jun;34(6):1415-25.
Neville C, Whalley D, McKenna SP, Le Comte M, Fortin PR. Adaptation and validation of the Rheumatoid Arthritis Quality of Life Scale for use in Canada. J Rheumatol. 2001 Jul 1;28(7):1505-10.
Perez-Gutthann S, Petri M, Hochberg MC. Comparison of two methods of classifying patients with systemic lupus erythematosus. J Rheumatol. 1991 Aug 1;18(8):1176-9.